CYT-002-NicQb, a therapeutic vaccine for the treatment of nicotine addiction

Current Opinion in Investigational Drugs

Volumn 8, Issue 1, 2007, Pages 71-77

  Heading, Christine E ^a  

^a OPEN UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYT 002 NICQB; NICOTINE VACCINE; PLACEBO; UNCLASSIFIED DRUG; NICOTINE; NICOTINE QBETA VACCINE; VACCINE;

CLINICAL TRIAL; DRUG METABOLISM; DRUG SCREENING; DRUG SYNTHESIS; FLU LIKE SYNDROME; HUMAN; INJECTION SITE REACTION; NONHUMAN; REVIEW; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; TOBACCO DEPENDENCE; CHEMISTRY; INTRAMUSCULAR DRUG ADMINISTRATION; METHODOLOGY; PHARMACEUTICS;

CLINICAL TRIALS; HUMANS; INJECTIONS, INTRAMUSCULAR; NICOTINE; TECHNOLOGY, PHARMACEUTICAL; TOBACCO USE DISORDER; VACCINES;

EID: 33947381833     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Human therapeutic cocaine vaccine: Safety and immunogenicity. Kosten TR, Rosen M, Bond J, Settles M, Roberts JS, Shields J, Jack L, Fox B VACCINE 2002 20 7-8 1196-1204
2. Cytos' Immunodrug for smoking addiction enters phase I clinical trial. Cytos Biotechnology AG PRESS RELEASE 2003 April 23
3. Tissue-dependent effects of immunization with a nicotine conjugate vaccine on the distribution of nicotine in rats. Satoskar SD, Keyler DE, LeSage MG, Raphael DE, Ross CA, Pentel PR INT IMMUNOPHARMACOL 2003 3 7 957-970
4. Cytos initiated phase II clinical trial with its Immunodrug for nicotine addiction. Cytos Biotechnology AG PRESS RELEASE 2004 January 14
5. Xenova's antismoking vaccine improves quit rate in phase I trial. Xenova Group plc PRESS RELEASE 2005 March 03
6. The American College Of Cardiology - Annual Scientific Session 2005, Orlando, FL, USA. Susman E IDDB MEETING REPORT 2005 March 05-09
7. 2004 Annual report - Cytos Biotechnology AG. Cytos Biotechnology AG ANNUAL REPORT 2005 February 08
8. Vaccine to treat nicotine addiction achieves proof of efficacy in phase II clinical trial. Cytos Biotechnology AG PRESS RELEASE 2005 May 14 •• Details of the phase II study design and results are reported.
9. American Society of Clinical Oncology - 41st Annual Meeting (Part I) - Overnight report, Orlando, FL, USA, 13-17 May 2005. Shah S IDDB MEETING REPORT 2005 May 13-17
10. A therapeutic vaccine for nicotine dependence: Results of a phase I and a randomized phase II study. Cornuz J, Klingler K, Mueller P, Jungi F, Cerny T PROC AM SOC CLIN ONCOL 2005 24 Abs 1008
11. New data: Pfizer's varenicline is an effective and safe treatment for smoking cessation. Pfizer Inc PRESS RELEASE 2005 November 15
12. Nabi's anti-smoking vaccine well tolerated in phase II study. Nabi Biopharmaceuticals PRESS RELEASE 2006 January 25
13. Cytos's nicotine addiction vaccine more effective at higher dose. Cytos Biotechnology AG PRESS RELEASE 2006 February 02 • A summary of the information concerning the phase II and dose optimization study, with particular reference to effective antibody titers.
14. Xenova's phase II smoking cessation trial approved in UK. Celtic Pharmaceutical Holdings LP PRESS RELEASE 2006 May 08
15. Nabi begins proof-of-concept study of antismoking vaccine. Nabi Biopharmaceuticals PRESS RELEASE 2006 May 24
16. Pfizer's chantix launched in US as smoking cessation aid. Pfizer Inc PRESS RELEASE 2006 August 01
17. A therapeutic vaccine for nicotine dependence: Preclinical efficacy, and phase I safety and immunogenicity. Maurer P, Jennings GT, Willers J, Rohner F, Lindman Y, Roubicek K, Renner WA, Muller P, Bachmann M EUR J IMMUNOL 2005 35 7 2031-2040 •• The only detailed report of preclinical and phase I investigations of CYT-002-NicQb, including data on antibody titers, specificity, nicotine binding and influence on nicotine tissue distribution (mice only).
18. 7-subunit-containing nicotinic acetylcholine. Laviolette SR, van der Kooy D PSYCHOPHARMACOLOGY (BERL) 2003 166 3 306-313
19. The biological, social and clinical basis of drug addiction: Commentary and debate. Altman J, Everitt BJ, Glautier S, Markou A, Nutt D, Oretti R, Phillips GD, Robbins TW. PSYCHOPHARMACOLOGY (BERL) 1996 125 4 285-345
20. Reply to: Hasman A and Holm S. Nicotine conjugate vaccine: Is there a right to a smoking future? Cerny T, Cerny EH J MED ETHICS 2005 31 9 558
21. Safety, tolerability and efficacy of a therapeutic vaccine for nicotine dependence. Cornuz J, Jungi T, Cerney T, Klinger K, Maurer P, Müller P LUNG CANCER 2005 49 2 S189-S190
22. Duration of smoking abstinence and success in quitting. Gilpin EA J NAT CANCER INT 1997 89 8 572-576
23. Intention to quit smoking, attempts to quit, and successful quitting among Hong Kong Chinese smokers: Population prevalence and predictors. Abdullah AS, Yam HK AM J HEALTH PROMOT 2005 19 5 346-354
24. Cyt002-NicQb: A novel vaccine for nicotine addiction. Cytos Biotechnology AG COMPANY PRESENTATION 2006 October 30
25. 2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: A randomized controlled trial. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR J AM MED ASSOC 2006 296 1 56-63
26. Bupropion for the treatment of nicotine withdrawal and craving. Mooney ME, Sofuoglu M EXPERT REV NEUROTHER 2006 6 7 965-981
27. Non-nicotine pharmacotherapies for nicotine dependence. Dudas MM, George TP ESSENT PSYCHOPHARMACOL 2005 6 3 158-172
28. Nicotine replacement therapy for smoking cessation. Silagy C, Lancaster T, Stead L, Mant D, Fowler G COCHRANE DATABASE SYST REV 2004 3 CD000146
29. Antidepressants for smoking cessation. Hughes J, Stead L, Lancaster T Cochrane DATABASE SYST REV 2004 18 4 CD000031
30. Rimonabant: A cannabinoid receptor blocker for the treatment of metabolic and cardiovascular risk factors. Tonstad S NUTR METAB CARDIOVASC DIS 2006 16 2 156-162
31. Optimizing smoking cessation strategies. Andrews J NURSE PRACT 1998 23 8 47-58
32. Tobacco Free Initiative (TFI). World Health Organization 2006 November 03 http://www.who.int/tobacco/en/
33. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Hatsukami DK, Rennard S, Jorenby D, Fiore M, Koopmeiners J, de Vos A, Horwith G, Pentel PR CLIN PHARMACOL THER 2005 78 5 456-467
34. Results of a phase 2, multi-center, randomized, double-blinded, placebo-controlled, parallel-arm, dose comparison study to assess the immunogenicity and safety of 3′-aminomethylnicotine-P. aeruginosa R-exoprotein A conjugate vaccine (NicVAX) administered to smokers. Hatsukami D, Rennard S, Jorenby D, Pentel P, de Vos A, Horwith G NICOTINE TOBACCO RES 11th Annual Meeting, Prague, Czech Republic 2005 Abs
35. Pfizer's CHAMPIX launched in the UK. Pfizer Inc PRESS RELEASE 2006 November 30